CN119137121A - 可用作NLRP3衍生物的吡啶并-[3,4-d]哒嗪胺衍生物 - Google Patents

可用作NLRP3衍生物的吡啶并-[3,4-d]哒嗪胺衍生物 Download PDF

Info

Publication number
CN119137121A
CN119137121A CN202380037553.1A CN202380037553A CN119137121A CN 119137121 A CN119137121 A CN 119137121A CN 202380037553 A CN202380037553 A CN 202380037553A CN 119137121 A CN119137121 A CN 119137121A
Authority
CN
China
Prior art keywords
compound
pyrido
pyridazin
amino
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037553.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·多里奇
A·切夫森
S·西布拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vantex Treatment Usa
Original Assignee
Vantex Treatment Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by Vantex Treatment Usa filed Critical Vantex Treatment Usa
Publication of CN119137121A publication Critical patent/CN119137121A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380037553.1A 2022-03-25 2023-03-24 可用作NLRP3衍生物的吡啶并-[3,4-d]哒嗪胺衍生物 Pending CN119137121A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US17/704,983 2022-03-25
US202263420930P 2022-10-31 2022-10-31
US63/420,930 2022-10-31
US202363443874P 2023-02-07 2023-02-07
US63/443,874 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (1)

Publication Number Publication Date
CN119137121A true CN119137121A (zh) 2024-12-13

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037553.1A Pending CN119137121A (zh) 2022-03-25 2023-03-24 可用作NLRP3衍生物的吡啶并-[3,4-d]哒嗪胺衍生物

Country Status (13)

Country Link
EP (1) EP4499638A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510414A (cg-RX-API-DMAC7.html)
KR (1) KR20250005125A (cg-RX-API-DMAC7.html)
CN (1) CN119137121A (cg-RX-API-DMAC7.html)
AU (1) AU2023238121A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246681A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002855A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013702A2 (cg-RX-API-DMAC7.html)
IL (1) IL315842A (cg-RX-API-DMAC7.html)
MX (1) MX2024011697A (cg-RX-API-DMAC7.html)
PE (1) PE20250605A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345836A (cg-RX-API-DMAC7.html)
WO (1) WO2023183943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors

Also Published As

Publication number Publication date
AU2023238121A1 (en) 2024-10-10
IL315842A (en) 2024-11-01
CO2024013702A2 (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
EP4499638A1 (en) 2025-02-05
MX2024011697A (es) 2024-11-08
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CL2024002855A1 (es) 2025-02-14
CA3246681A1 (en) 2023-09-28
PE20250605A1 (es) 2025-02-26
WO2023183943A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP7620120B2 (ja) Nlrp3を阻害するためのピリダジン化合物
TW202345836A (zh) 可用作NLRP3衍生物之吡啶并-〔3,4-d〕噠嗪胺衍生物
US12312351B2 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN119212978A (zh) 用于抑制nlrp3的氧代吲哚啉基酰胺衍生物及其用途
KR20230157535A (ko) Nlrp3을 저해하기 위한 피리다진 화합물
HK40100030A (en) Compounds for inhibiting nlrp3 and uses thereof
BR122024000756A2 (pt) Compostos inibidores de nlrp3, derivado isotópico dos mesmos, composição farmacêutica que compreende os mesmos, bem como uso dos ditos compostos para tratar ou prevenir uma doença ou distúrbio relacionado a nlrp3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination